Close Menu

NEW YORK – Biocept and Aegea Biotechnologies said Thursday that they have signed an agreement under which they will codevelop a PCR-based COVID-19 assay using the Switch-Blocker technology co-owned by the two firms. 

Switch-Blocker is currently the core of Biocept's suite of blood-based assays for cancer mutation detection. The underlying intellectual property is jointly owned by Biocept and Aegea, with Aegea holding exclusive rights in the field of infectious disease, and Biocept has certain rights within the field of clinical oncology.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.